Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1868 - Nivolumab in Non Small Cell Lung Cancer: French evaluation of use, current practices and medico economic approach


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research




Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


F. GRUDE1, R. Corre2, T. Urban3, J. Bennouna4, G. De Chabot5, T. Chatellier6, F. Denis7, R. Descourt8, J. Douillard9, C. Ricordel2, O. Molinier10, F. Pinquie5, G. Robinet8, M. Travers11, B. Moiteaux12, D. Deniel Lagadec13, F. Marhuenda14

Author affiliations

  • 1 Cancer Observatory, ICO Paul Papin, 49055 - Angers/FR
  • 2 Pneumology, CHU de Pontchaillou, 35033 - Rennes/FR
  • 3 Pneumology, CHU Angers, 49933 - Angers/FR
  • 4 Pneumology, CHU de Nantes - Laennec, 44800 - Saint Herblain/FR
  • 5 Pneumology, CHU Angers, 49 933 - Angers/FR
  • 6 Oncology, Clinique Mutualiste de l'Estuaire, 44606 - Saint Nazaire/FR
  • 7 Oncology, Clinique Victor Hugo Le Mans, 72000 - Le Mans/FR
  • 8 Oncology, C.H.U. Brest - Hôpital Morvan, 29609 - Brest/FR
  • 9 Division Of Medical And Scientific Affairs, ESMO - European Society for Medical Oncology, 6962 - Lugano - Viganello/CH
  • 10 Pneumology, Centre Hospitalier Du Mans, 72037 - Le Mans/FR
  • 11 Iae, Université de Nantes, 44000 - NANTES/FR
  • 12 Iae, university of Nantes, 44000 - Nantes/FR
  • 13 Cancer Observatory, CHRU BREST, 29609 - BREST/FR
  • 14 Cancer Observatory, ICO Paul Papin, 49055 - ANGERS/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1868


In 2016, nivolumab could be prescribed according to French registration in stage IIIB/IV NSCLC after disease progression with prior platinum-based chemotherapy and TKI therapy for patients with EGFR mutation. The Observatory of Drugs, Medical Devices and Therapeutic Innovations (OMEDIT), a network from the Health Ministry has evaluated the use, current practices and medico-economic approach in the Bretagne and Pays de la Loire areas.


All consenting adult patients with stage IIIB/IV NSCLC who initiated nivolumab (3 mg/kg every 2 weeks) in 2016 were included. Minimum follow-up for survival was 12 months. Sex, age, mutation profile, toxicities, Clinic Benefit (CB: pts with complete/partial response/stable disease as the best response), progression-free survival (PFS) and overall survival (OS) have been studied for ECOG PS 0-1 pts (according to registration).


377 pts with squamous (113 pts), non-squamous (197) and undifferentiated (67) NSCLC have been included. The median number of courses was 8 (1-54). 140 pts (37%) had 1 to 4 courses, 67 pts (18%) 5 to 8 courses and 170 pts (45%) more than 8. 247 pts were treated in 2nd line, 98 in 3rd line. All lines combined, CB was experienced by 212 pts (56%). For these pts, median course was 17 (1-54), mPFS and mOS were 4.6 months and 15.0 months, respectively. No difference on survival has been noticed according to histology, treatment line, age (cut-off 70 y), grade III/IV toxicity. However, mPFS and mOS were lower in ECOG PS ≥ 2 pts than in PS0-1 pts: 2.4 months vs 4.6 m (p < 0.01) for PFS and 3.7 m vs 15.0 m (p < 0.001) for OS. 20% of pts presented grade III/IV toxicities. These pts presented a better CB (74% vs 56%, p = 0.002). In 2016-2017, this treatment, for pts initiated in 2016 only, cost 15.8 million euros (drug, hospitalisation and transportation). 86% of these costs were dedicated to pts who experienced CB.


In a real-life setting, survival outcomes and toxicities with nivolumab in advanced NSCLC are comparable to literature data. ECOG PS ≥ 2 pts presented shorter survival than PS0-1 pts. Interestingly, 86% of the cost incurred for these treatments was to pts with CB. Updated data will be shown at the meeting.

Clinical trial identification

Legal entity responsible for the study

Cancer Observatory, OMEDIT B and PL.


Has not received any funding.

Editorial Acknowledgement


R. Corre: Board, invitation Congress: BMS. J-Y. Douillard: CMO: ESMO. O. Molinier: Expert advice: BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.